Severe asthma trajectories in adults: findings from the NORDSTAR cohort

BACKGROUND

There is limited evidence on the pathways leading to severe asthma and we are presently unable to effectively predict the progression of the disease. We aimed to describe the longitudinal trajectories leading to severe asthma and to describe clinical events preceding disease progression in a nationwide population of patients with severe asthma.

METHODS

We conducted an observational study based on Swedish data from the NORdic Dataset for aSThmA Research (NORDSTAR) research collaboration platform. We identified adult patients with severe asthma in 2018 according to the European Respiratory Society/American Thoracic Society definition and used latent class analysis to identify trajectories of asthma severity over a 10-year retrospective period from 2018.

RESULTS

Among 169 128 asthma patients, we identified 4543 severe asthma patients. We identified four trajectories of severe asthma that were labelled as: trajectory 1 "consistently severe asthma" (n=389 (8.6%)), trajectory 2 "gradual onset severe asthma" (n=942 (20.7%)), trajectory 3 "intermittent severe asthma" (n=1685 (37.1%)) and trajectory 4 "sudden onset severe asthma" (n=1527 (33.6%)). "Consistently severe asthma" had a higher daily inhaled corticosteroid dose and more prevalent osteoporosis compared with the other trajectories. Patients with "gradual onset severe asthma" and "sudden onset severe asthma" developed type 2-related comorbidities concomitantly with development of severe asthma. In the latter group, this primarily occurred within 1-3 years preceding onset of severe asthma.

CONCLUSIONS

Four distinct trajectories of severe asthma were identified illustrating different patterns of progression of asthma severity. This may eventually enable the development of better preventive management strategies in severe asthma.

Problematic opioid use among osteoarthritis patients with chronic post-operative pain after joint replacement: analyses from the BISCUITS study

OBJECTIVES

Opioids are commonly used to manage pain, despite an increased risk of adverse events and complications when used against recommendations. This register study uses data of osteoarthritis (OA) patients with joint replacement surgery to identify and characterize problematic opioid use (POU) prescription patterns.

METHODS

The study population included adult patients diagnosed with OA in specialty care undergoing joint replacement surgery in Denmark, Finland, Norway, and Sweden during 1 January 2011 to 31 December 2014. Those with cancer or OA within three years before the first eligible OA diagnosis were excluded. Patients were allocated into six POU cohorts based on dose escalation, frequency, and dosing of prescription opioids post-surgery (definitions were based on guidelines, previous literature, and clinical experience), and matched on age and sex to patients with opioid use, but not in any of the six cohorts. Data on demographics, non-OA pain diagnoses, cardiovascular diseases, psychiatric disorders, and clinical characteristics were used to study patient characteristics and predictors of POU.

RESULTS

13.7% of patients with OA and a hip/knee joint replacement were classified as problematic users and they had more comorbidities and higher pre-surgery doses of opioids than matches. Patients dispensing high doses of opioids pre-surgery dispensed increased doses post-surgery, a pattern not seen among patients prescribed lower doses pre-surgery. Being dispensed 1-4,500 oral morphine equivalents in the year pre-surgery or having a non-OA pain diagnosis was associated with post-surgery POU (OR: 1.44-1.50, and 1.11-1.20, respectively).

CONCLUSIONS

Based on the discovered POU predictors, the study suggests that prescribers should carefully assess pain management strategies for patients with a history of comorbidities and pre-operative, long-term opioid use. Healthcare units should adopt risk assessment tools and ensure that these patients are followed up closely. The data also demonstrate potential areas for further exploration in improving patient outcomes and trajectories.

Prevalence and management of severe asthma in the Nordic countries – findings from the NORDSTAR cohort

Background

Real-life evidence on prevalence and management of severe asthma is limited. Nationwide population registries across the Nordic countries provide unique opportunities to describe prevalence and management patterns of severe asthma at population level.

Aim

In nationwide register data from Sweden, Norway, and Finland, we examined the prevalence of severe asthma and the proportion of severe asthma patients being managed in specialist care.

Methods

This is a cross-sectional study based on the NORdic Dataset for aSThmA Research (NORDSTAR) research collaboration platform. We identified patients with severe asthma in adults (≥18 years) and in children (6–17 years) in 2018 according to the ERS/ATS definition. Patients managed in specialist care were those with an asthma-related specialist outpatient contact (only available in Sweden and Finland).

Results

Overall, we identified 598 242 patients with current asthma in Sweden, Norway, and Finland in 2018. Among those, the prevalence of severe asthma was 3.5%, 5.4% and 5.2% in adults and 0.4%, 1.0%, and 0.3% in children in Sweden, Norway, and Finland, respectively. In Sweden and Finland, 37% and 40% of adult patients with severe asthma and ≥2 exacerbations were managed in specialist care; in children the numbers were 56% and 41%, respectively.

Conclusion

In three Nordic countries, population-based nationwide data demonstrated similar prevalence of severe asthma. In children, severe asthma was a rare condition. Notably, a large proportion of patients with severe asthma was not managed by a respiratory specialist, suggesting the need for increased recognition of severe asthma in primary care.

Dimensional reduction in Bose-Einstein condensed clouds of atoms confined in tight potentials of any geometry and any interaction strength

Motivated by numerous experiments on Bose-Einstein condensed atoms which have been performed in tight trapping potentials of various geometries [elongated and/or toroidal (annular)], we develop a general method which allows us to reduce the corresponding three-dimensional Gross-Pitaevskii equation for the order parameter into an effectively one-dimensional equation, taking into account the interactions (i.e., treating the width of the transverse profile variationally) and the curvature of the trapping potential. As an application of our model we consider atoms which rotate in a toroidal trapping potential. We evaluate the state of lowest energy for a fixed value of the angular momentum within various approximations of the effectively one-dimensional model and compare our results with the full solution of the three-dimensional problem, thus getting evidence for the accuracy of our model.

Numerical solution of the stationary multicomponent nonlinear Schrödinger equation with a constraint on the angular momentum

We formulate a damped oscillating particle method to solve the stationary nonlinear Schrödinger equation (NLSE). The ground-state solutions are found by a converging damped oscillating evolution equation that can be discretized with symplectic numerical techniques. The method is demonstrated for three different cases: for the single-component NLSE with an attractive self-interaction, for the single-component NLSE with a repulsive self-interaction and a constraint on the angular momentum, and for the two-component NLSE with a constraint on the total angular momentum. We reproduce the so-called yrast curve for the single-component case, described in [A. D. Jackson et al., Europhys. Lett. 95, 30002 (2011)], and produce for the first time an analogous curve for the two-component NLSE. The numerical results are compared with analytic solutions and competing numerical methods. Our method is well suited to handle a large class of equations and can easily be adapted to further constraints and components.

The ethics of hormesis – no fuss?

It has been argued that the phenomenon of hormesis should prompt us to revise current regulatory policy in order to take beneficial effects of small doses of various agents into account. I argue that three problems – the comparative smallness of hormetic effects, the fine-tuning problem, and the problem of aggregated actions – should lead us not to overemphasize the importance of hormesis for policy, and that they, if anything, points towards a non-consequentialist approach to the ethics of risk.